Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Singular Genomics Systems, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 SC 13G/A Flynn James E reports a 7.4% stake in Singular Genomics Systems, Inc.
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "### EX-99.1 Singular Genomics Systems, Inc. Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 505 $ - $ 1,368 $ - Cost of revenue 597 - 1,404 - Gross margin - - Operating expenses: Research and development 12,624 12,061 24,854 22,707 Selling, general and administrative 14,887 12,182 28,091 23,556 Total operating expenses 27,511 24,243 52,945 46,263 Loss from operations Other income : Interest expense Interest and other income 2,295 428 4,299 584 Total other income 2,025 261 3,770 275 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 72,510,020 70,779,326 72,218,280 70,893,059 EX-99.1 Singular Genomics Systems, Inc. Bala..."
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "###"
07/20/2023 8-K Quarterly results
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Singular Genomics Systems, Inc. Statements of Operations Three Months Ended March 31, 2023 2022 Revenue $ 863 $ - Cost of revenue 807 - Gross margin 56 - Operating expenses: Research and development 12,230 10,645 Selling, general and administrative 13,204 11,375 Total operating expenses 25,434 22,020 Loss from operations Other income : Interest expense Interest and other income 2,004 156 Total other income 1,745 14 Net loss $ $ Net loss per share: Basic and diluted net loss per share $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,926,412 71,011,041 EX-99.1 Singular Genomics Systems, Inc. Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 129,283 $ 74,266 Short-term investments 96,790 170,310 Accounts rec..."
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "Singular Genomics Systems, Inc. Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Revenue $ 765 $ - $ 765 $ - Cost of revenue 789 - 789 - Gross margin - - Operating expenses: Research and development 10,760 9,455 46,199 32,655 Selling, general and administrative 11,746 10,218 47,264 28,624 Total operating expenses 22,506 19,673 93,463 61,279 Loss from operations Other income : Interest expense Change in fair value of convertible promissory notes"
02/14/2023 SC 13G/A Glezer Eli N. reports a 6% stake in Singular Genomics Systems, Inc.
02/14/2023 SC 13G/A Revelation Alpine, LLC reports a 1.7% stake in Singular Genomics Systems, Inc.
02/10/2023 SC 13G/A Flynn James E reports a 9.1% stake in Singular Genomics Systems, Inc.
02/01/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/01/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue San Diego, CA, January 9, 2023 - Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited fourth quarter 2022 revenue. The company shipped five G4 instruments through December 31, 2022 and recognized approximately $700 thousand in preliminary unaudited revenue during the fourth quarter 2022 for those instruments that met revenue recognition criteria. “We are pleased to have finished the year on a strong note. We executed to our plan in Q4, shipping several G4 systems which are now installed and running in customer labs,” said Drew S..."
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Financial Statements and Exhibits  Interactive Data
Docs: "Singular Genomics Systems, Inc. Condensed Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 12,732 $ 8,910 $ 35,439 $ 23,200 Selling, general and administrative 11,962 8,551 35,518 18,406 Total operating expenses 24,694 17,461 70,957 41,606 Loss from operations Other income : Interest and other income 1,115 84 1,699 628 Interest expense Change in fair value of convertible promissory notes"
10/04/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
08/22/2022 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Singular Genomics Systems, Inc. Condensed Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 12,061 $ 7,682 $ 22,707 $ 14,289 Selling, general and administrative 12,182 6,201 23,556 9,855 Total operating expenses 24,243 13,883 46,263 24,144 Loss from operations Other income : Interest and other income 428 413 584 543 Interest expense Change in fair value of convertible promissory notes - - Change in fair value of warrant liability - 22 - Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 70,779,326 31,628,921 70,893,059 21,696,142 Singular Genomics Systems, Inc. Condensed Balance Sheet..."
08/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/28/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/25/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Singular Genomics Systems, Inc. 2021 Equity Incentive Plan, as amended, and form of agreements thereunder",
"Singular Genomics Systems, Inc. 2021 Equity Incentive Plan, as amended, and form of agreements thereunder"
07/25/2022 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
07/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy